The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
The value of therapists using games with children or teens in therapy sessions is sometimes misunderstood but can be a highly ...
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. Click here to read more ...
Android Auto 17.2 is one of the most bug-ridden releases in a very long time, with users now complaining of audio issues ...
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm ...
By registering the LongCat-2.0 repository under the open-source MIT License, Meituan positions the architecture with maximum ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Full terms and rules for the Mashable at VidCon 2026 sweepstakes.
Levacetylleucine (Aqneursa) improved neurologic symptoms and functioning in adults and children with ataxia-telangiectasia in ...
Shares of uniQure QURE soared 78.4% on June 17, after the company announced a major regulatory milestone for AMT-130, its investigational gene therapy for Huntington's disease. The stock, however, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results